Indeed, a phase I/IIa trial utilizing co-inhibition of LAG-3 and PD-1 has already shown improved efficacy in melanomas compared to anti-PD-1 monotherapy, and this will soon be investigated in sarcomas as well (https://clinicaltrials.gov/ Identifier: NCT04095208. The gene discussed is LAG3; the disease is sarcoma.